-

Forge Biologics to Present at Morgan Stanley’s 20th Annual Global Healthcare Conference

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Christina Perry, Senior Vice President of Finance & Investor Relations, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, in New York, NY. Concurrently, Forge will host one-on-one meetings with interested investors.

Forge’s presentation is expected to begin at 10:00 a.m. ET. A live webcast of the presentation will be available by visiting the Company’s Events website at https://www.forgebiologics.com/news/#events and may be accessed for 90 days.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Forge Biologics


Release Summary
Morgan Stanley Co Presentation by Christina Perry
Release Versions

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations
Investors@forgebiologics.com

Social Media Profiles
More News From Forge Biologics

Forge Biologics Announces Seven Presentations at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced that it will deliver seven presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, taking place May 11-15, 2026, in Boston. The presentations include two technical sessions, co-chairing an oral abstract session, and four scientific posters. “As the gene therapy field enters a crit...

Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership

SAN FRANCISCO & COLUMBUS, Ohio--(BUSINESS WIRE)--Epicrispr Biotechnologies (“Epicrispr”), a clinical-stage company pioneering gene-modulating therapies, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to support the development and manufacturing of EPI-321, Epicrispr’s investigational AAV gene therapy for facioscapulohumeral muscular dystrophy (FSHD). Through this collaboration...

Forge Biologics Among Select Global CDMOs to Earn My Green Lab® Certification Across All Laboratories and cGMP Suites

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced it has achieved My Green Lab® Certification, the global gold standard for laboratory sustainability best practices, across all of its laboratories and manufacturing suites. This milestone reflects a company-wide effort to embed sustainable practices across Forge’s operation, reinforcing its commitment to operational excellen...
Back to Newsroom